clinical trial · NCT07372118
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Condition
Humanis Saglık Anonim Sirketi·phase1·completed·n = 32
Type 2 Diabetes Mellitus (T2DM)Empagliflozin / Metformin HCl XR TabletsSynjardy® XR (empagliflozin and metformin hydrochloride extended-release Tablets)
brief summary
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in fast condition.
started
Sep 27, 2025
primary completion
Dec 29, 2025
completion
Jan 7, 2026
last updated
Jan 28, 2026
official title
An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover, Oral Bioequivalence Study of Test Product and Reference Product of Synjardy XR Tablets 25mg/1000mg in Healthy, Adult, Human Subjects Under Fasting Condition.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol